-
公开(公告)号：US09650447B2
公开(公告)日：2017-05-16
申请号：US13697693
申请日：2011-05-13
CPC分类号： C07K19/00 , C07K14/472
摘要： Provided herein are compositions and methods directed to soluble proteins which can selectively deliver modulators of complement activity. Targeted delivery of these modulators is accomplished by selectively mutating particular amino acids in a targeting protein portion of the composition corresponding to at least the first two N-terminal SCR domains of CR2. Depending on the particular combination of mutations introduced into the targeting portion, a complement activity modulator can be selectively delivered to particular ligands of CR2 at sites where complement system activation or suppression is desired.
-
公开(公告)号：US08703140B2
公开(公告)日：2014-04-22
申请号：US11843617
申请日：2007-08-22
IPC分类号： A61K39/395 , C07K16/00
CPC分类号： C07K16/18 , A61K39/3955 , A61K45/06 , A61K2039/505 , A61K2039/544 , C07K2317/34 , C07K2317/76 , C07K2319/30
摘要： Disclosed are novel inhibitors of the alternative complement pathway and particularly, novel anti-factor B antibodies. Also disclosed is the use of such inhibitors to reduce or prevent airway hyperresponsiveness and/or airway inflammation by selectively inhibiting the alternative complement pathway, thereby treating diseases in which such conditions play a role. Also disclosed is the use of such inhibitors to reduce or prevent other diseases and conditions, including ischemia-reperfusion injury, by inhibition of the alternative complement pathway.
-
公开(公告)号：US20110229497A1
公开(公告)日：2011-09-22
申请号：US13120125
申请日：2009-09-22
IPC分类号： A61K39/395 , A61P43/00
CPC分类号： C07K16/18 , A61K38/00 , A61K38/1709 , A61K38/177 , C07K14/4721 , C07K2317/54 , C07K2317/55 , C07K2319/70 , C12N9/88 , C12Y402/01002
摘要： Provided herein are compositions, including pharmaceutical compositions, and methods for modulating, i.e., stimulating or inhibiting, activity of the alternative complement pathway, and methods of identifying factor H-binding proteins.
摘要翻译： 本文提供了组合物，包括药物组合物和调节，即刺激或抑制替代补体途径的活性的方法，以及鉴定因子H结合蛋白的方法。
-
公开(公告)号：US20110015127A1
公开(公告)日：2011-01-20
申请号：US12782526
申请日：2010-05-18
IPC分类号： A61K38/17 , C07K14/435 , C12N15/12 , C12N15/63 , C12N5/07 , A61P27/02 , A61P19/02 , A61P9/10 , A61P13/12
CPC分类号： C07K14/705 , A61K38/00 , C07K14/47 , C07K14/70596 , C07K2319/00
摘要： The invention provides a CR2-FH molecule comprising a CR2 portion comprising CR2 protein or a fragment thereof and a FH portion comprising a factor H protein or a fragment thereof, and pharmaceutical compositions comprising a CR2-FH molecule. Also provided are methods of using the compositions for treatment diseases in which the alternative complement pathway is implicated, such as age-related macular degeneration, rheumatoid arthritis, and ischemia reperfusion.
摘要翻译： 本发明提供包含CR2部分的CR2-FH分子，其包含CR2蛋白或其片段和包含因子H蛋白或其片段的FH部分和包含CR2-FH分子的药物组合物。 还提供了使用组合物治疗涉及替代补体途径的疾病的方法，例如年龄相关性黄斑变性，类风湿性关节炎和缺血再灌注。
-
公开(公告)号：US08540997B2
公开(公告)日：2013-09-24
申请号：US13162434
申请日：2011-06-16
IPC分类号： A61K39/00
CPC分类号： C07K14/70596 , A61K38/00 , C07K14/705 , C07K16/2896 , C07K2319/00
摘要： Modulation of the complement system represents a therapeutic modality for numerous pathologic conditions associated with complement activation. In a strategy to prepare complement inhibitors that are targeted to sites of complement activation and disease, compositions comprising a complement inhibitor linked to complement receptor (CR) 2 are disclosed. The disclosed are compositions can be used in methods of treating pathogenic diseases and inflammatory conditions by modulating the complement system.
摘要翻译： 补体系统的调节代表了与补体激活相关的许多病理状况的治疗方式。 在制备靶向补体活化和疾病部位的补体抑制剂的策略中，公开了包含与补体受体（CR）2连接的补体抑制剂的组合物。 所公开的是组合物可以用于通过调节补体系统来治疗病原性疾病和炎性病症的方法。
-
公开(公告)号：US08007804B2
公开(公告)日：2011-08-30
申请号：US10534772
申请日：2003-11-13
CPC分类号： C07K14/70596 , A61K38/00 , C07K14/705 , C07K16/2896 , C07K2319/00
摘要： Modulation of the complement system represents a therapeutic modality for numerous pathologic conditions associated with complement activation. In a strategy to prepare complement inhibitors that are targeted to sites of complement activation and disease, compositions comprising a complement inhibitor linked to complement receptor (CR) 2 are disclosed. The disclosed are compositions can be used in methods of treating pathogenic diseases and inflammatory conditions by modulating the complement system.
摘要翻译： 补体系统的调节代表了与补体激活相关的许多病理状况的治疗方式。 在制备靶向补体活化和疾病部位的补体抑制剂的策略中，公开了包含与补体受体（CR）2连接的补体抑制剂的组合物。 所公开的是组合物可以用于通过调节补体系统来治疗病原性疾病和炎性病症的方法。
-
公开(公告)号：US20080299114A1
公开(公告)日：2008-12-04
申请号：US12049233
申请日：2008-03-14
申请人： Woodruff Emlen , V. Michael Holers , Peter Flynn
发明人： Woodruff Emlen , V. Michael Holers , Peter Flynn
IPC分类号： A61K39/395 , C07K16/00 , A61P11/00 , A61P33/00 , A61P31/12
CPC分类号： C07K16/40 , A61K2039/505 , C07K16/18 , C07K16/461 , C07K2317/55 , C07K2317/56 , C07K2317/92
摘要： This invention relates to humaneered anti-factor B antibodies and antigen-binding fragments thereof with reduced immunogenicity. The humaneered anti-factor B antibodies and antigen-binding fragments thereof are derived from murine monoclonal antibody 1379, which binds factor B in the third short consensus repeat (“SCR”) domain and selectively inhibits activation of the alternative complement pathway by preventing formation of the C3bBb complex. The invention also relates to methods of treating diseases or disorders in which activation of the alternative complement pathway plays a role, and methods of selectively inhibiting activation of the alternative complement pathway in an individual in need thereof.
摘要翻译： 本发明涉及具有降低的免疫原性的受人尊敬的抗因子B抗体及其抗原结合片段。 人类的抗因子B抗体及其抗原结合片段衍生自鼠单克隆抗体1379，其在第三短共有重复（“SCR”）结构域中结合因子B，并通过预防形成的方法选择性地抑制替代补体途径的活化 C3bBb复合物。 本发明还涉及治疗其中补体途径的活化发挥作用的疾病或病症的方法，以及在有需要的个体中选择性抑制替代补体途径活化的方法。
-
公开(公告)号：US20080221011A1
公开(公告)日：2008-09-11
申请号：US11821370
申请日：2007-06-21
CPC分类号： C07K14/705 , A61K38/00 , C07K14/47 , C07K14/70596 , C07K2319/00
摘要： The invention provides a CR2-FH molecule comprising a CR2 portion comprising CR2 protein or a fragment thereof and a FH portion comprising a factor H protein or a fragment thereof, and pharmaceutical compositions comprising a CR2-FH molecule. Also provided are methods of using the compositions for treatment diseases in which the alternative complement pathway is implicated, such as age-related macular degeneration, rheumatoid arthritis, and ischemia reperfusion.
摘要翻译： 本发明提供包含CR2部分的CR2-FH分子，其包含CR2蛋白或其片段和包含因子H蛋白或其片段的FH部分和包含CR2-FH分子的药物组合物。 还提供了使用组合物治疗涉及替代补体途径的疾病的方法，例如年龄相关性黄斑变性，类风湿性关节炎和缺血再灌注。
-
9.发明申请TREATMENT OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, HEMOLYTIC ANEMIAS AND DISEASE STATES INVOLVING INTRAVASCULAR AND EXTRAVASCULAR HEMOLYSIS 审中-公开涉及腔内和体外溶解的复合氧化蛋白尿，溶血性病变和疾病状态的治疗公开(公告)号：US20130029912A1
公开(公告)日：2013-01-31
申请号：US13505150
申请日：2010-11-05
CPC分类号： C07K16/18 , A61K38/1709 , A61K38/178 , C07K14/47 , C07K14/70596 , C07K2319/00
摘要： Methods for treating subjects having complement-mediated hemolytic disorders, such as paroxysmal nocturnal hemoglobinuria (PNH) and other hemolytic anemias, the method comprising administering an effective amount of a composition that inhibits the activity of the complement alternative pathway.
摘要翻译： 用于治疗患有补体介导的溶血障碍的受试者的方法，例如阵发性夜间血红蛋白尿（PNH）和其它溶血性贫血，所述方法包括施用有效量的抑制补体替代途径活性的组合物。
-
10.发明申请LIGAND-SPECIFIC NON-ANTIBODY COMPOUNDS THAT INHIBIT CR2 ACTIVATION AND METHODS OF USE THEREOF 审中-公开抑制CR2活化的配体特异性非抗体化合物及其使用方法公开(公告)号：US20120108492A1
公开(公告)日：2012-05-03
申请号：US13119706
申请日：2009-09-18
CPC分类号： C07K16/2896 , C07K7/06 , C07K7/08 , C07K14/005 , C07K2317/34 , C07K2317/76 , C12N2710/16222
摘要： The present invention describes a novel non-antibody ligand-specific compound that selectively binds to a complement receptor type 2 (CR2) protein, a ligand thereof, or both, wherein the compound competitively inhibits CR2 ligand's binding to a CR2 protein in a standard assay. The present invention also describes compositions and methods of use thereof.
摘要翻译： 本发明描述了选择性结合补体受体2型（CR2）蛋白，其配体或两者的新型非抗体配体特异性化合物，其中所述化合物在标准测定中竞争性地抑制CR2配体与CR2蛋白的结合 。 本发明还描述了其组合物及其使用方法。
-
-
-
-
-
-
-
-
-
搜索结果
25 条记录 (耗时 0.032 秒)
